125 related articles for article (PubMed ID: 10188884)
21. Pasireotide (SOM230), a novel multireceptor-targeted somatostatin analogue, is well tolerated when administered as a continuous 7-day subcutaneous infusion in healthy male volunteers.
Petersenn S; Unger N; Hu K; Weisshaar B; Zhang Y; Bouillaud E; Reséndiz KH; Wang Y; Mann K
J Clin Pharmacol; 2012 Jul; 52(7):1017-27. PubMed ID: 21673137
[TBL] [Abstract][Full Text] [Related]
22. Advanced breast cancer: response to somatostatin.
Stolfi R; Parisi AM; Natoli C; Iacobelli S
Anticancer Res; 1990; 10(1):203-4. PubMed ID: 1970716
[TBL] [Abstract][Full Text] [Related]
23. Feasibility, endocrine and anti-tumour effects of a triple endocrine therapy with tamoxifen, a somatostatin analogue and an antiprolactin in post-menopausal metastatic breast cancer: a randomized study with long-term follow-up.
Bontenbal M; Foekens JA; Lamberts SW; de Jong FH; van Putten WL; Braun HJ; Burghouts JT; van der Linden GH; Klijn JG
Br J Cancer; 1998; 77(1):115-22. PubMed ID: 9459155
[TBL] [Abstract][Full Text] [Related]
24. [Blood prolactin level of breast and endometrial cancer patients during surgical intervention].
Pozdniakov VV; Bobrov IuF; Gamaiunova VB; Evtiukhin AI; Frid IA
Vopr Onkol; 1984; 30(2):9-14. PubMed ID: 6702135
[TBL] [Abstract][Full Text] [Related]
25. Endocrine effects of combined somatostatin analog and bromocriptine therapy in women with advanced breast cancer.
Manni A; Boucher AE; Demers LM; Harvey HA; Lipton A; Simmonds MA; Bartholomew M
Breast Cancer Res Treat; 1989 Dec; 14(3):289-98. PubMed ID: 2575406
[TBL] [Abstract][Full Text] [Related]
26. Biological and clinical evaluation of lanreotide (BIM 23014), a somatostatin analogue, in the treatment of advanced breast cancer. A pilot study by the I.T.M.O. Group. Italian Trials in Medical Oncology.
Di Leo A; Ferrari L; Bajetta E; Bartoli C; Vicario G; Moglia D; Miceli R; Callegari M; Bono A
Breast Cancer Res Treat; 1995 Jun; 34(3):237-44. PubMed ID: 7579488
[TBL] [Abstract][Full Text] [Related]
27. Vapreotide: BMY 41606, RC 160, Sanvar.
Drugs R D; 2003; 4(5):326-30. PubMed ID: 12952505
[TBL] [Abstract][Full Text] [Related]
28. A phase I study of the somatostatin analogue somatuline in patients with metastatic hormone-refractory prostate cancer.
Figg WD; Thibault A; Cooper MR; Reid R; Headlee D; Dawson N; Kohler DR; Reed E; Sartor O
Cancer; 1995 Apr; 75(8):2159-64. PubMed ID: 7535186
[TBL] [Abstract][Full Text] [Related]
29. The effect of treatment with 4-hydroxyandrostenedione or medroxyprogesterone acetate on human breast tumour regression.
Coldham NG; Lai LC; Ghilchik MW; Walker MM; James VH; Reed MJ
Anticancer Res; 1993; 13(3):753-8. PubMed ID: 8317908
[TBL] [Abstract][Full Text] [Related]
30. Radioimmunoassay for octapeptide analogs of somatostatin: measurement of serum levels after administration of long-acting microcapsule formulations.
Mason-Garcia M; Vaccarella M; Horvath J; Redding TW; Groot K; Orsolini P; Schally AV
Proc Natl Acad Sci U S A; 1988 Aug; 85(15):5688-92. PubMed ID: 2899894
[TBL] [Abstract][Full Text] [Related]
31. Potential role for somatostatin analogues in breast cancer: rationale and description of an ongoing trial.
Pollak M; Gallant K; Poisson R; Harris A
Metabolism; 1992 Sep; 41(9 Suppl 2):119-20. PubMed ID: 1355585
[TBL] [Abstract][Full Text] [Related]
32. Somatostatin analogue RC-160 inhibits the growth of transplanted colon cancer in rats.
Qin Y; Schally AV; Willems G
Int J Cancer; 1991 Mar; 47(5):765-70. PubMed ID: 1672306
[TBL] [Abstract][Full Text] [Related]
33. [Effect of phenformin and miscleron on the blood somatomedin activity level in breast cancer].
Vasil'eva IA; Bershteĭn LM; Ostroumova MN; Dil'man VM
Vopr Onkol; 1980; 26(9):34-6. PubMed ID: 7423902
[TBL] [Abstract][Full Text] [Related]
34. Stabilization of Octastatin, a somatostatin analogue. Preparation of freeze-dried products for parenteral injection.
Pourrat H; Barthomeuf C; Pourrat A; Cottier PE; Ibrahim H
Biol Pharm Bull; 1995 May; 18(5):766-71. PubMed ID: 7492997
[TBL] [Abstract][Full Text] [Related]
35. [Radioimmunochemical analysis in the evaluation of the effectiveness of drug therapy of breast cancer in women of reproductive age].
Tkacheva GA; Moroz LV; Ivanov VM
Vestn Akad Med Nauk SSSR; 1984; (5):54-60. PubMed ID: 6741250
[No Abstract] [Full Text] [Related]
36. [Blood prolactin levels and functional status of the sympatho-adrenal system during complex treatment of breast cancer].
Sidorenko LN; Korovin KF; Popova SP; Egor'kova AS; Shpanskaia LS
Vestn Khir Im I I Grek; 1982 Aug; 129(8):13-5. PubMed ID: 7135749
[No Abstract] [Full Text] [Related]
37. N-terminal acylation of somatostatin analog with long chain fatty acids enhances its stability and anti-proliferative activity in human breast adenocarcinoma cells.
Dasgupta P; Singh A; Mukherjee R
Biol Pharm Bull; 2002 Jan; 25(1):29-36. PubMed ID: 11824552
[TBL] [Abstract][Full Text] [Related]
38. Vapreotide, a new somatostatin analogue in the palliative management of obstructive ileus in advanced cancer.
Stiefel F; Morant R
Support Care Cancer; 1993 Jan; 1(1):57-8. PubMed ID: 7511473
[TBL] [Abstract][Full Text] [Related]
39. Relation between tumour size and plasma prolactin levels in premenopausal patients with breast carcinoma. A preliminary report.
Olsson H; Ewers SB; Landin-Olsson M; Ranstam J
Acta Radiol Oncol; 1985; 24(1):57-9. PubMed ID: 2984903
[TBL] [Abstract][Full Text] [Related]
40. [Letter: Prolactin and breast cancer].
Rolandi E; Barreca T; Masturzo P; Polleri A; Indiveri F; Barabino A
Nouv Presse Med; 1974 Dec; 3(45):2743. PubMed ID: 4459869
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
